Article

Alcon receives two Frost & Sullivan awards in 2005

Frost & Sullivan recognized Alcon Inc., with the Product of the Year and the Company of the Year awards for 2005.

The product award was for the AcrySof ReSTOR multifocal IOL. "The lens truly represents a new paradigm in cataract surgery, which will provide the nearly 3 million people in the United States who have cataract surgery each year with the option for a new standard of care and improved vision," said Frost & Sullivan research analyst Mansi Kothari, PhD.

The analyst firm said that AcrySof ReSTOR is unlike other advanced IOLs because the product combines apodization, diffraction, and refraction, thereby circumventing the dependence on eye muscles for accommodation. Clinical trials show 80% of patients never wore glasses or bifocals after surgery.

The company award recognizes Alcon's growing market penetration, satisfaction among prescribers and patients, and successful market strategy and employee satisfaction in the ocular hypertension and open angle glaucoma market as well.

"A 2005 Frost & Sullivan survey showed Alcon as the most respected company by ophthalmologists and optometrists in the U.S. glaucoma medication market due to its excellence in first-line glaucoma medication, and its dedication in facilitating access to medication for non-insured patients through coupons, samples, and concise needy-patient forms for physicians," said Dhiraj Ajmani, another Frost & Sullivan research analyst.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.